【摘要】 目的探讨西酞普兰治疗广泛性焦虑症的临床疗效及安全性。方法将60例广泛性焦虑症患者随机分为两组,分别给予西酞普兰与阿普唑仑治疗,观察6w。于治疗前及治疗后第1w、2w、4w、6w末采用汉密顿焦虑量表、焦虑自评量表及副反应量表评定疗效及安全性。结果治疗6w末,西酞普兰组显效率73%,有效率90%;阿普唑仑组分别为63%,83%。两组疗效相当(χ2=0.69,P>0.05)。汉密顿焦虑量表评分治疗1w末起两组总分及各因子分均较治疗前显著下降(P均<0.01),并随治疗时间的延续呈持续性下降。两组间比较除精神性焦虑因子分治疗1w末有显著性差异(t=1.83,P<0.05)外,其余均无显著性差异(P均>0.05)。焦虑自评量表评分两组治疗6w末均较治疗前有显著下降(P<0.01),组间比较无显著性差异(P>0.05)。西酞普兰组不良反应较阿普唑仑组少且轻微,患者依从性好。结论西酞普兰抗焦虑疗效肯定,与阿普唑仑相当,安全性高,依从性好。更多还原

【Abstract】 Objective To explore the clinical efficacy and safety of citalopram in the treatment of generalized anxiety disorder.Methods 60 patients with generalized anxiety disorderwere randomly divided into citalopram and alprazolam group for 6 weeks.Curative effects were assessed with the Hamilton Anxiety Sacle(HAMA),the Self-rating Anxiety Scale(SAS)and adverse effects with the Treatment Emergent Symptom Scale(TESS)before treatment and at the end of the 1st,2nd,4th and 6th week treatment.Results At the end of the 6th week,excellence and effectiveness rates were respectively 73% and 90% in the citalopram and 63% and 83% in the alprazolam group,which showed that the 2 groups had therapeutic equivalence(P>0.05).Since the end of the 1st week,the HAMA total score and all factors’ scores lowered more significantly compared with pretreatment(all P<0.01)and did continiously as treatment time went on.There were significant differences in psychogenic anxiety at the end of the 1st week(P<0.05)and no in the rest factors’ scores(all P>0.05)between the two groups.At the end of the 6th week,the SAS scores of both groups lowered more significantly compared with pretreatment(both P<0.01)and there was no significant difference in intragroup comparison(P>0.05).Adverse effects of the citalopram were fewer and milder,and patients’ adherence was better.Conclusion Citalopram has a posiitive antianxious effectiveness equivalent to alprazolam and higher safety and better compliance.更多还原